This study is testing a drug called IBI363 in people with advanced solid cancers like melanoma, non-small cell lung cancer, colorectal cancer, and renal cell cancer. IBI363 is a monoclonal antibody, a type of medicine that targets specific cells. The main goal is to see how many people respond to the treatment (objective response rate, ORR) over two years. You might be able to join if you are 18 or older, have a good performance status (meaning you can do most daily activities), and are expected to live at least 3 months. The study is currently unclear about its recruitment status and plans to enroll 178 participants.

Study design

This is a Phase 2, open-label study, meaning both you and your doctors will know you are receiving IBI363. It will involve about 178 participants across multiple centers.

What's involved

You would receive IBI363 as an intravenous (IV) infusion every 2 or 3 weeks. Treatment continues until your disease gets worse, side effects are too much, you withdraw consent, or for up to 24 months.

Compensation

Not stated in the trial record.

Follow-up

The main measure of success (objective response rate) will be tracked for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.